惠州市锦好医疗科技股份有限公司 独立董事专门会议关于 2025 年限制性股票激励计划 预留权益授予激励对象名单的审查意见及公示情况说明的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于 2025 年 12 月 31 日召开 第三届董事会第十九次会议，审议通过了《关于公司 2025 年限制性股票激励计划授予 的 激 励对 象名 单的议 案 》， 并于 2026 年 1 月 6 日在 北京 证 券交 易所 官 网 （http://www.bse.cn）上披露了《2025 年限制性股票激励计划预留权益授予的激励对象 名单》（公告编号 2026-003）。公司独立董事专门会议结合公示情况对激励对象进行了 审查，相关公示情况及审查情况如下： 证券代码：920925 证券简称：锦好医疗 公告编号：2026-006 2.列入公司《激励对象名单》的人员具备《中华人民共和国公司法》《公司章程》 等法律、法规和规范性文件规定的任职资格，不存在《上市公司股权激励管理办法 ...

Core Viewpoint - The company JinHao Medical has reported an increase in stock price and provided updates on the use of idle funds for purchasing financial products, indicating a strategic approach to asset management [1]. Group 1: Stock Performance - As of January 13, 2026, JinHao Medical's stock closed at 26.66 yuan, up 1.21% from the previous trading day [1]. - The stock opened at 26.6 yuan, reached a high of 27.5 yuan, and a low of 26.2 yuan, with a trading volume of 2.4 billion yuan and a turnover rate of 16.12% [1]. Group 2: Financial Product Investment - The company announced the use of up to 100 million yuan of idle self-owned funds to purchase low-risk, high-liquidity bank financial products, approved by the board on October 27, 2025 [1]. - As of January 13, 2026, the remaining balance of the purchased financial products was 60.2 million yuan, representing 16.92% of the company's audited net assets as of the end of 2024 [1]. - The company has added a purchase of 10 million yuan in structured deposits from the Bank of China, with a term of 119 days and an expected annual yield of 0.6% or 1.9%, funded by self-owned capital [1].

关于使用部分闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 惠州市锦好医疗科技股份有限公司 证券代码：920925 证券简称：锦好医疗 公告编号：2026-005 （一） 本次委托理财产品的基本情况 （一）购买理财产品的审议情况 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召开第三届董事会第十七次会议审议通过《关于使用部分闲置自有资金购买银 行理财产品的议案》。为提高公司资金使用效率，在确保资金安全、不影响公司 正常经营的前提下，公司合理利用部分暂时闲置自有资金购买银行理财产品。使 用额度不超过人民币 10,000 万元的自有闲置资金购买安全性高、流动性好、风 险较低的理财产品，在此额度内可以循环滚动使用。具体内容详见公司 2025 年 10 月 29 日在北京证券交易所（www.bse.cn）披露的《关于使用部分闲置自有资 金购买银行理财产品的公告》（公告编号：2025-122）。 （二）购买理财产品 ...

Group 1 - The report highlights the launch of "ChatGPT Health" by OpenAI, which integrates health-related conversations and connects to electronic medical records, indicating a significant potential market for AI in healthcare [9][12] - The "Artificial Intelligence + Manufacturing" initiative aims to achieve reliable supply of core AI technologies and maintain a leading position in the industry by 2027, with specific targets including the application of 3-5 general large models in manufacturing and the creation of 100 high-quality industrial datasets [12][14] - The report identifies key sectors such as AI healthcare, AI pharmaceuticals, and AI biomanufacturing as focal points for development, proposing measures like building intelligent drug discovery platforms and smart supply chain management systems [16][12] Group 2 - The North Exchange's biopharmaceutical sector saw a weekly increase of 5.85%, with medical devices rising by 7.81%, indicating strong market performance [23][26] - Among the biopharmaceutical companies, 90.48% experienced stock price increases, with notable performers including BeiYikang (+45.1%) and XinGanjian (+10.46%) [33][34] - As of January 9, 2026, there are 15 companies in the biopharmaceutical sector awaiting approval on the North Exchange, with an average projected revenue of 424 million yuan for 2024 [34][38] Group 3 - The report emphasizes the importance of AI in enhancing drug development efficiency and supply chain management, aiming to reduce costs and time in pharmaceutical processes [16][12] - The global AI healthcare market is projected to reach approximately $26.65 billion in 2024, with a compound annual growth rate (CAGR) of 38.8% expected until 2033 [18][17] - The Chinese AI healthcare industry is expected to grow from 97.3 billion yuan in 2023 to 159.8 billion yuan by 2028, reflecting significant growth potential in this sector [18][19]

Group 1 - Jinhai Medical (920925) experienced a decline of 14.76% today, with a turnover rate of 32.59% and a transaction volume of 517 million yuan, showing a fluctuation of 14.83% [2][3] - The stock was listed on the daily turnover board due to its turnover rate reaching 32.59%, with a net selling amount of 158 million yuan from brokerage seats [3] - The top five brokerage seats accounted for a total transaction volume of 224 million yuan, with a buying amount of 33.13 million yuan and a selling amount of 191 million yuan, resulting in a net selling of 158 million yuan [3] Group 2 - The largest buying brokerage was Dongfang Caifu Securities, Lhasa Tuanjie Road First Securities, with a buying amount of 6.9757 million yuan, while the largest selling brokerage was Guotai Haitong Securities, Chongqing Jiefangbei, with a selling amount of 58.6743 million yuan [3] - Detailed trading information shows that multiple brokerage seats from Dongfang Caifu Securities were involved in buying, with significant amounts also sold by other brokerages [3]

Group 1 - The report highlights the significant progress in the pharmaceutical and healthcare system reforms during the "14th Five-Year Plan" period, with a focus on grassroots healthcare and urban-rural integration [1][12] - The "15th Five-Year Plan" emphasizes the support for innovative drugs and medical devices, aiming to enhance the healthcare system and promote the development of traditional Chinese medicine [1][17] - The report indicates that the 11th batch of national drug procurement successfully implemented innovative goals, including maintaining clinical stability and quality assurance [1][14] Group 2 - As of December 31, 2025, the total market capitalization of 21 pharmaceutical and biotechnology companies on the North Exchange reached 748.30 billion, reflecting a growth of 45.81% from the beginning of the year [2][20] - The average market capitalization of these companies increased to 35.63 billion, up 38.87% from the previous year [2][21] - The North Exchange's pharmaceutical sector is primarily composed of chemical pharmaceuticals (38.10%), medical devices (28.57%), and biological products (19.05%) [2][31] Group 3 - In 2025, the North Exchange's pharmaceutical and biotechnology sector experienced a year-on-year increase of 37.38%, ranking third among various sectors [3][54] - The report notes that 80.95% of the pharmaceutical companies on the North Exchange saw an increase in their stock prices throughout the year [3][42] - The top-performing companies in terms of stock price growth included JinHao Medical (+174.08%), NuoSiLanDe (+105.64%), and BeiYiKang (+76.39%) [3][45] Group 4 - The report indicates that the North Exchange's pharmaceutical companies had a PE TTM average of 73X by the end of 2025, with a peak of 119X in August [2][34] - The distribution of valuations shows that the North Exchange has a higher proportion of companies with significant losses compared to other exchanges, with 28.57% of companies in the loss category [2][40] - The report highlights that the North Exchange's pharmaceutical sector is characterized by a high concentration of companies in the 100X and above PE TTM range [2][43]

Group 1 - The stock price of Jinhai Medical (920925) closed at 27.84 yuan on January 7, 2026, down 14.76% from the previous trading day, with a total market capitalization of 2.741 billion yuan [1] - The stock opened at 31.44 yuan, reached a high of 31.44 yuan, and a low of 27.38 yuan, with a trading volume of 5.17 billion yuan and a turnover rate of 32.59% [1] - Jinhai Medical announced a 2025 restricted stock incentive plan, granting a total of 200,000 shares to three incentive objects, with senior management Zhang Liang receiving 100,000 shares (50.00%), Yuan Jinpeng receiving 50,000 shares (25.00%), and core employee Zhong Mei receiving 50,000 shares (25.00%) [1]

Core Viewpoint - On January 7, 2026, Jinhao Medical (920925) was featured on the stock exchange's "Dragon and Tiger List" due to a significant trading volume, with a turnover rate of 32.59% and a transaction amount of 517 million yuan [1][2]. Trading Activity Summary - The total trading volume for Jinhao Medical on that day was 18.02 million shares, with a total transaction value of 517 million yuan [1]. - The top buying seat was from Dongfang Caifu Securities, which purchased approximately 6.98 million yuan worth of shares [2]. - The top selling seat was from Guotai Haitong Securities, which sold approximately 58.67 million yuan worth of shares [2]. Detailed Trading Data - The following are the top trading departments: - Dongfang Caifu Securities, Lhasa Tuanjie Road First Securities Office: Buy 6,975,733.27 yuan, Sell 5,376,321.64 yuan [2]. - Bank of China International Securities, Shenzhen Branch: Buy 6,745,707.59 yuan, Sell 34,084 yuan [2]. - Dongfang Caifu Securities, Lhasa East Ring Road Second Securities Office: Buy 6,466,188.67 yuan, Sell 2,651,309.67 yuan [2]. - Guotai Haitong Securities, Chongqing Liberation Monument Office: Buy 0 yuan, Sell 58,674,322.99 yuan [2].

公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 一、限制性股票激励计划预留权益的分配 1、激励计划获授限制性股票预留权益在各对象间的分配情况如下： | | | | 获授的限 | 占激励计划预留 | 涉及标的股票数量 | | --- | --- | --- | --- | --- | --- | | 序号 | 姓名 | 职务 | 制性股票 | 部分拟授出权益 | 占激励计划公告日 | | | | | 数量（股） | 总量的比例 | 股本总额的比例 | | 1 | 张亮 | 高级管理人员 | 100,000 | 50.00% | 0.10% | | 2 | 袁金鹏 | 高级管理人员 | 50,000 | 25.00% | 0.05% | | 3 | 钟梅 | 核心员工 | 50,000 | 25.00% | 0.05% | | | 合计 | | 200,000 | 100.00% | 0.20% | 证券代码：920925 证券简称：锦好医疗 公告编号：2026-003 注：以上百分比计算结果出现差异是由于四 ...

证券代码：920925 证券简称：锦好医疗 公告编号：2026-002 惠州市锦好医疗科技股份有限公司 第三届董事会第十九次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 12 月 31 日 2.会议召开地点：公司会议室 会议应出席董事 7 人，出席和授权出席董事 7 人。 董事王敏因公以通讯方式参与表决。 董事王芳因公以通讯方式参与表决。 董事李忠轩因工作原因以通讯方式参与表决。 3.会议召开方式：现场与通讯方式相结合 4.发出董事会会议通知的时间和方式：2025 年 12 月 26 日以书面方式发出 5.会议主持人：王敏先生 6.会议列席人员：高级管理人员 7.召开情况合法合规的说明： 本次会议的召集、召开程序符合《公司法》、《公司章程》和《董事会议事规 则》的相关规定。 （二）会议出席情况 董事郑能恒因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于公司 2025 年限制性股票激励计划预留 ...